

REMARKS

Upon entry of this amendment, Claims 28, 31-46 and 50 are pending. Claim 39-45 are withdrawn from consideration. Applicants amended claims 28. The specification (see, for example, definitions in pages 5 to 7) provides support for the amendments. No new matter has been introduced by the instant amendments.

35 U.S.C. §112, Second Paragraph

Claims 28, 31-37 stand rejected under 35 U.S.C. §112, second paragraph as allegedly being indefinite. The Examiner asserts the terms "heteroaryl" or "heterocyclyl" to be vague and indefinite. Applicants respectfully disagree.

To expedite prosecution, applicants amend claim 28 to add the specific definition of heteroaryl and heterocyclyl. Support to the amendments can be found for example in the definition section for heteroaryl and heterocyclyl and in the Examples.

Allowable Subject Matter

Applicants acknowledge and thank the Examiner for indicating allowable subject matter.

Conclusion


Applicants have addressed each and every issue set forth by the Examiner. Applicants respectfully submit that the present application is in good condition for allowance.

If the Examiner believes for any reason that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (617) 871-4125.

If necessary, the Commissioner is hereby authorized in this, concurrent, and further replies, to charge payment or credit any overpayment to Deposit Account No. 50-4409 for any additional fees under 37 C.F.R. §1.16 or under 37 C.F.R. §1.17, particularly extension of time fees.

Novartis Institutes for Biomedical Research
NIBR Patents
220 Massachusetts Ave.
Cambridge, MA 02139
(617) 871-4125

Respectfully submitted


Mark W. Milstead
Attorney for Applicant
Reg. No. 45,825

Date: June 29, 2009

30